Myrio Therapeutics has announced a collaborative research initiative with the University of Pennsylvania”s Perelman School of Medicine and NYU Langone Health aimed at accelerating the progress of next-generation T cell immunotherapies specifically for solid tumors. This partnership combines the distinctive expertise of each organization to address the significant challenges in developing effective cancer treatments.
The collaboration focuses on three main areas: peptide HLA (pHLA) binder discovery, bispecific T-cell engager development, and the advancement of cell immunotherapies. By merging their strengths, the partners intend to gain deeper insights into the mechanisms behind these technologies and assess their therapeutic potential. The immediate plan involves establishing a formal company and initiating seed funding to propel these innovations toward clinical trials.
Dr. Graeme Wald, CEO of Myrio Therapeutics, expressed enthusiasm for the partnership, describing it as a powerful combination of leading technologies and talent dedicated to improving treatments for solid tumors. “This is a magnificent case of putting the best technologies and people together to develop products for solid tumor treatments,” he stated, emphasizing the collaborative effort”s potential impact.
Dr. Daniel J Powell Jr., a professor of Pathology and Laboratory Medicine at the Perelman School of Medicine, highlighted the significance of the collaboration, noting that creating tolerable yet effective treatments is a major challenge in cancer therapy. “By uniting the diverse expertise of these three groups, we are in an excellent position to create safe, effective, durable therapy for difficult-to-treat cancers,” he remarked.
Mark Yarmarkovich, Assistant Professor at NYU Langone Health, also conveyed his excitement about the partnership. He noted the unique complementarity of the technologies involved, stating, “We are thrilled to move forward quickly with this collaboration, bringing together uniquely complementary technologies to tackle the challenges of solid tumors.” He added that the combined platforms present an opportunity to develop truly differentiated therapies, which could significantly alter the treatment landscape and provide meaningful benefits for patients.
Myrio Therapeutics is a biotechnology firm focused on creating next-generation precision immunotherapies that target oncogenic mutations using its proprietary pHLA binder technology. The company aims to deliver transformative therapies for solid tumors, leveraging its extensive antibody library and robust preclinical pipeline. For further information about Myrio Therapeutics, visit myriotx.com.
